Joanna Thomas, MD
Family Medicine · Lynchburg, VANPI 1275768855
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Novo Nordisk at 24.3% of the total. Reporting peaked in 2024 at $1,258 and has fallen 51.6% since, to $609 in 2025.
Across 120 payments — averaging $20.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$595
- Lilly USA, LLC$287
- Pfizer$247
- Abbott$244
- Boehringer Ingelheim$207
- Amgen$159
- plus $705 from 19 others
What the payments were for
- Food & beverage$2,43199%
- Entertainment$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 27 | $595 |
| Lilly USA, LLC | 14 | $287 |
| Pfizer | 15 | $247 |
| Abbott | 5 | $244 |
| Boehringer Ingelheim | 11 | $207 |
| Amgen | 10 | $159 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $136 |
| AbbVie | 5 | $116 |
| GSK | 4 | $63 |
| Dexcom, Inc. | 3 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $41 |
| Astellas Pharma US Inc | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $30 |
| Genentech USA, Inc. | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $21 |
| Corium, LLC | 1 | $18 |
| Philips North America LLC | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $18 |
| Bayer | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Optos, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| AstraZeneca | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$145
- Saxenda$107
How this compares
$2,445 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metformin Hcl ErMetformin Hcl | 17 | $166 |
| Atorvastatin Calcium | 28 | $93 |
| Metoprolol Tartrate | 13 | $48 |
| Cyclobenzaprine Hcl | 11 | $43 |
| Gabapentin | 11 | $27 |
| Lisinopril | 11 | $6 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Lynchburg
- Kimberly CombsLynchburg$26K
- Craig PetryLynchburg$19K
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.